{"id":62972,"date":"2026-04-13T15:25:30","date_gmt":"2026-04-13T07:25:30","guid":{"rendered":"https:\/\/flcube.com\/?p=62972"},"modified":"2026-04-13T15:25:30","modified_gmt":"2026-04-13T07:25:30","slug":"neurocrine-biosciences-to-acquire-soleno-therapeutics-for-2-9-billion-adding-three-first-in-class-commercial-assets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62972","title":{"rendered":"Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets"},"content":{"rendered":"\n<p><strong>Neurocrine Biosciences, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NBIX:NASDAQ\">NASDAQ: NBIX<\/a>) has announced a definitive agreement to acquire fellow U.S. biopharmaceutical company <strong>Soleno Therapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/SLNO:NASDAQ\">NASDAQ: SLNO<\/a>) in an all-cash transaction valued at approximately <strong>$2.9 billion<\/strong>, or <strong>$53 per share<\/strong>. The acquisition will immediately bolster Neurocrine\u2019s commercial portfolio with three <strong>first-in-class therapies<\/strong> across rare and neuropsychiatric disorders, adding over <strong>$3 billion in combined annual revenue<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-amp-portfolio-snapshot\">Deal &amp; Portfolio Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Indication<\/th><th>2025 Revenue<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Ingrezza<\/strong><\/td><td>Tardive Dyskinesia, Huntington&#8217;s Chorea<\/td><td>$2.51B<\/td><td>VMAT2 Market Leader<\/td><\/tr><tr><td><strong>Crenessity<\/strong><\/td><td>Classic Congenital Adrenal Hyperplasia (CAH)<\/td><td>$301M<\/td><td>Approved Dec 2024<\/td><\/tr><tr><td><strong>Vykat XR<\/strong><\/td><td>Prader-Willi Syndrome (PWS)<\/td><td>$190M<\/td><td>Approved Mar 2025<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><\/td><td><strong>~$2.9B Equity Value<\/strong><\/td><td>$53\/share<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Revenue Diversification:<\/strong> The deal transforms Neurocrine from a single-product (Ingrezza) leader into a multi-franchise specialty pharma company with a diversified, high-margin revenue stream.<\/li>\n\n\n\n<li><strong>Rare Disease Leadership:<\/strong> Acquiring Crenessity and Vykat XR establishes Neurocrine as a dominant player in the high-value, orphan drug space for endocrine and genetic neurological disorders.<\/li>\n\n\n\n<li><strong>Commercial Synergy:<\/strong> Neurocrine\u2019s existing, highly effective commercial infrastructure can be leveraged to accelerate the uptake of Crenessity and Vykat XR, maximizing their market potential.<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Beyond the commercial assets, the acquisition includes Soleno\u2019s late-stage pipeline and R&amp;D capabilities in complex metabolic and neurological conditions.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-context-amp-china-strategy\">Global Context &amp; China Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>International Partnerships:<\/strong> Neurocrine has already laid groundwork for global expansion, notably in China, through strategic collaborations with <strong>Biocytogen Pharmaceuticals<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688796:SHA\">SHA: 688796<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/2315:HKG\">HKG: 2315<\/a>) and <strong>TransThera Sciences<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2617:HKG\">HKG: 2617<\/a>) to co-develop novel antibodies and <strong>NLRP3 inhibitors<\/strong>.<\/li>\n\n\n\n<li><strong>Integrated Growth Model:<\/strong> This acquisition complements Neurocrine\u2019s external innovation strategy, providing a powerful commercial engine to potentially launch future products from its partnered pipelines.<\/li>\n\n\n\n<li><strong>Market Confidence:<\/strong> The significant premium offered for Soleno reflects strong confidence in the long-term growth trajectory and durability of its newly approved assets in competitive but underserved markets.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief details a proposed acquisition that is subject to customary closing conditions, including regulatory approvals and Soleno shareholder approval. The financial projections for the acquired assets are based on historical 2025 results. Future performance may vary due to market competition, reimbursement challenges, and other commercial risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced a definitive agreement to acquire fellow U.S. biopharmaceutical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1519,1214,4181,4424,4688,4423,24,4547,4687],"class_list":["post-62972","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biocytogen-pharmaceuticals","tag-hkg-2315","tag-hkg-2617","tag-nasdaq-nbix","tag-nasdaq-slno","tag-neurocrine-biosciences","tag-rare-orphan-disease-drugs","tag-sha-688796","tag-soleno-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced a definitive agreement to acquire fellow U.S. biopharmaceutical company Soleno Therapeutics, Inc. (NASDAQ: SLNO) in an all-cash transaction valued at approximately $2.9 billion, or $53 per share. The acquisition will immediately bolster Neurocrine\u2019s commercial portfolio with three first-in-class therapies across rare and neuropsychiatric disorders, adding over $3 billion in combined annual revenue.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62972\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets\" \/>\n<meta property=\"og:description\" content=\"Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced a definitive agreement to acquire fellow U.S. biopharmaceutical company Soleno Therapeutics, Inc. (NASDAQ: SLNO) in an all-cash transaction valued at approximately $2.9 billion, or $53 per share. The acquisition will immediately bolster Neurocrine\u2019s commercial portfolio with three first-in-class therapies across rare and neuropsychiatric disorders, adding over $3 billion in combined annual revenue.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62972\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T07:25:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62972#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62972\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets\",\"datePublished\":\"2026-04-13T07:25:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62972\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biocytogen Pharmaceuticals\",\"HKG: 2315\",\"HKG: 2617\",\"NASDAQ: NBIX\",\"NASDAQ: SLNO\",\"Neurocrine Biosciences\",\"Rare \\\/ orphan disease drugs\",\"SHA: 688796\",\"Soleno Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62972#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62972\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62972\",\"name\":\"Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-13T07:25:30+00:00\",\"description\":\"Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced a definitive agreement to acquire fellow U.S. biopharmaceutical company Soleno Therapeutics, Inc. (NASDAQ: SLNO) in an all-cash transaction valued at approximately $2.9 billion, or $53 per share. The acquisition will immediately bolster Neurocrine\u2019s commercial portfolio with three first-in-class therapies across rare and neuropsychiatric disorders, adding over $3 billion in combined annual revenue.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62972#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62972\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62972#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets - Insight, China&#039;s Pharmaceutical Industry","description":"Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced a definitive agreement to acquire fellow U.S. biopharmaceutical company Soleno Therapeutics, Inc. (NASDAQ: SLNO) in an all-cash transaction valued at approximately $2.9 billion, or $53 per share. The acquisition will immediately bolster Neurocrine\u2019s commercial portfolio with three first-in-class therapies across rare and neuropsychiatric disorders, adding over $3 billion in combined annual revenue.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62972","og_locale":"en_US","og_type":"article","og_title":"Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets","og_description":"Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced a definitive agreement to acquire fellow U.S. biopharmaceutical company Soleno Therapeutics, Inc. (NASDAQ: SLNO) in an all-cash transaction valued at approximately $2.9 billion, or $53 per share. The acquisition will immediately bolster Neurocrine\u2019s commercial portfolio with three first-in-class therapies across rare and neuropsychiatric disorders, adding over $3 billion in combined annual revenue.","og_url":"https:\/\/flcube.com\/?p=62972","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-13T07:25:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62972#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62972"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets","datePublished":"2026-04-13T07:25:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62972"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biocytogen Pharmaceuticals","HKG: 2315","HKG: 2617","NASDAQ: NBIX","NASDAQ: SLNO","Neurocrine Biosciences","Rare \/ orphan disease drugs","SHA: 688796","Soleno Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62972#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62972","url":"https:\/\/flcube.com\/?p=62972","name":"Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-13T07:25:30+00:00","description":"Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced a definitive agreement to acquire fellow U.S. biopharmaceutical company Soleno Therapeutics, Inc. (NASDAQ: SLNO) in an all-cash transaction valued at approximately $2.9 billion, or $53 per share. The acquisition will immediately bolster Neurocrine\u2019s commercial portfolio with three first-in-class therapies across rare and neuropsychiatric disorders, adding over $3 billion in combined annual revenue.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62972#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62972"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62972#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62972"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62972\/revisions"}],"predecessor-version":[{"id":62973,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62972\/revisions\/62973"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}